Who: Cedars-Sinai Heart Institute
What: Iron nanoparticles infused into the bloodstream to treat heart attack damage. The combined nanoparticle enabled precise localization of the body’s own stem cells to the injured heart muscle.
Where: Stem cell therapeutics, peripheral vascular disease and asthma.
When: The process to grow cardiac-derived stem cells was developed by the researchers when originally based at Johns Hopkins University. Johns Hopkins has filed for a patent on that intellectual property and has licensed it to Capricor. The iron nanoparticle concept could be ready for human clinical studies in about three years.
